BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

The biggest change to Bristol is coming - the biggest since the aftermath of the Second World War - and most people don’t ...

To access these pages you must be a permanent member of University staff and registered on the UoB domain. Staff who are unable to access these pages or need additional access to student data should ...

Russia and other hostile states have become increasingly brazen in adopting “gray zone” attacks against Europe and the United States, leaving defense officials with a dilemma: How to respond ...

Multiple NASCAR drivers take part in the Tulsa Shootout finale It’s the fifth and final night of Micro Racing in Tulsa, ...

Beauty was extremely important in ancient Greece and not just for women but for men, as well. As admirers of beauty, ancient Greeks placed great emphasis on healthy skin, and, naturally, they ...